4 recruiting, 3 completed, 2 not yet recruiting, 1 active not recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Completed 3, Not yet recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow 18-O-demethylcervinomycin A2: new trials by email Literature Review of 18-O-demethylcervinomycin A2 trials Research Report on 18-O-demethylcervinomycin A2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies Sacituzumab Tirumotecan (Sac-TMT), Tagitanlimab - Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 80 | 2026-09-01 | 2026-07-31 |
| SKB500 Combinations in Patients With Small Cell Lung Cancer SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection - Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 80 | 2026-01-30 | 2026-05-08 |
| Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer SKB264 - Breast Cancer | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 40 | 2025-12-24 | 2026-01-27 |
| Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) Sacituzumab Tirumotecan, Tagitanlimab - Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 28 | 2025-09-22 | 2025-09-18 |
| SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer Sacituzumab tirumotecan, Tagitanlimab - ER+HER2- Breast Cancer | Phase 2 | Not yet recruiting | West China Hospital | 55 | 2025-09-01 | 2025-08-07 |
| SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer SKB264, KL-A167 - Triple-negative Breast Cancer and HR+/HER2- BC | Phase 2 | Completed | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 184 | 2022-08-17 | 2026-08-28 |
| KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma KL-A167, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Recurrent or Metastatic | Phase 3 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 295 | 2022-06-07 | 2026-05-08 |
| SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. SKB264, KL-A167, Carboplatin - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 110 | 2022-05-20 | 2026-05-12 |
| KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma KL-A167 Injection - Nasopharyngeal Carcinoma, Recurrent or Metastatic | Phase 2 | Completed | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 153 | 2019-03-06 | 2026-05-05 |
| An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma KL-A167 - Classical Hodgkin Lymphoma | Phase 2 | Completed | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 109 | 2018-08-01 | 2026-05-05 |
Recurrence (3) · Nasopharyngeal Carcinoma (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6) · Peking Union Medical College Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · Tianjin Medical University Second Hospital (1) · West China Hospital (1)
China (9)
Haitao Wang, Ph.D (1) · Yilong Wu (1)